Application 210212
- Type
- ANDA
- Sponsor
- MSN LABORATORIES PRIVATE LTD
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | TABLET; ORAL | 12.5MG/500MG | No | No |
| 002 | ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | TABLET; ORAL | 12.5MG/1000MG | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| alogliptin and metformin hydrochloride | ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | Padagis Israel Pharmaceuticals Ltd | 14d98490-4f8f-4d2f-a4e9-7a3d7a0199ba | 2026-08-25 | Boxed warning, Warnings, Adverse reactions | alogliptin and metformin hydrochloride ALOGLIPTIN AND METFORMIN HYDROCHLORIDE |
| KAZANO | ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | Takeda Pharmaceuticals America, Inc. | 83cb7914-a683-47bb-a713-f2bc6a596bd2 | 2026-08-17 | Boxed warning, Warnings, Adverse reactions | ALOGLIPTIN AND METFORMIN HYDROCHLORIDE |
| alogliptin and metformin hydrochloride | ALOGLIPTIN AND METFORMIN HYDROCHLORIDE | A-S Medication Solutions | 9112d6b9-4771-4194-886d-7db887470bcc | 2023-10-31 | Boxed warning, Warnings, Adverse reactions | alogliptin and metformin hydrochloride ALOGLIPTIN AND METFORMIN HYDROCHLORIDE |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 61150 | ORIG | 2019-12-04 |